SS
ACAD icon

SBI Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

SBI Securities’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.25K Buy
247
+125
+102% +$2.75K ﹤0.01% 2076
2026
Q1 		$2.72K Sell
122
-75
-38% -$1.79K ﹤0.01% 2303
2025
Q4 		$5.26K Sell
197
-607
-75% -$14.5K ﹤0.01% 1996
2025
Q3 		$17.2K Buy
804
+712
+774% +$16.8K ﹤0.01% 1520
2025
Q2 		$1.98K Sell
92
-100
-52% -$1.86K ﹤0.01% 2384
2025
Q1 		$3.19K Sell
192
-10
-5% -$182 ﹤0.01% 2077
2024
Q4 		$3.71K Buy
+202
New +$3.26K ﹤0.01% 2039

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SBI Securities's ACAD Position: Q2 2026 in Review

SBI Securities increased its Acadia Pharmaceuticals (ACAD) stake by 102% in Q2 2026, buying an estimated $2.75K and bringing the position to 247 shares worth $6.25K. The position accounts for ﹤0.01% of the portfolio, ranked #2076.

SBI Securities first reported a position in ACAD in Q4 2024 and has held it in 7 quarters since. The position peaked at $17.2K in Q3 2025. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • SBI Securities held 247 shares of Acadia Pharmaceuticals worth $6.25K as of Q2 2026.
  • SBI Securities bought 125 Acadia Pharmaceuticals shares in Q2 2026, an estimated $2.75K.
  • Acadia Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2076 holding.
  • SBI Securities first reported a position in Acadia Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Acadia Pharmaceuticals position peaked at $17.2K in Q3 2025.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.